Overall verdict
Neutral
4.5/10
1-year performance
+92.77%
Score breakdown
Up 92.8% over 1 year, 84% of the 52-week range.
Strongest: Growth 6.7/10. Weakest: Shareholder return 0.0/10.
5 analysts, target +0.1% vs the price.
Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nasdaq
United States
CEO
Andrew Toy
Founded
2014
Employees
724
Revenue / employee
2.7M USD
Next earnings
February 26, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.09%
- Bank of New York Mellon Corp0.21%
- Rest of the register97.70%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
5.59 USD
52-week low
1.58 USD
1-year performance
92.77%
Rising
Year-to-date performance
107.35%
Rising
Drawdown
-11.72%
Mild pullback
Position in the 52-week range
84% of range
Gross margin 12.2%, net margin 0.5%, ROE 3.4%.
Net margin
0.45%
Low
Sector 1.68%|S&P 13.40%
Gross margin
12.23%
Low
Return on equity (ROE)
3.40%
Low
Sector 10.99%|S&P 17.06%
Return on invested capital (ROIC)
3.40%
Free cash flow margin (FCF)
4.83%
Profit-to-cash conversion (FCF conversion)
10.62x
Margin stability
15.1 pts
Very uneven
Revenue to net income
Growth
6.7/10Revenue up 52.9% over 1 year, 22.9% a year over 5.
Revenue (trailing 12 months)
2.7Md USD
Revenue growth (1y)
52.89%
Hyper-growth
Revenue growth (3y)
-44.81%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
0.00%
Revised down
Valuation
0.9/10P/E 261.1x, forward P/E 81.3x, PEG 2.18.
P/E (TTM)
261.1x
Very expensive
Sector 28.8x|S&P 23.6x
Forward P/E
81.3x
Very expensive
EV / EBITDA
—
Sector 18.5x|S&P 15.5x
PEG
2.18
Very expensive
Sector 0.50|S&P 0.91
Market cap
2.6Md USD
Not scored for a bank or an insurer: its solidity is measured by regulatory capital ratios, which we do not collect.
Net debt / EBITDA
-4.0x
Gearing (net debt / equity)
-68.58%
Cash
78.3M USD
Cash / market cap
2.99%
Net debt
-268M USD
Equity
391M USD
Closed daily candles, 2 years
Last close on November 10, 2026: 4.93 USD
- MM204.63
- MM504.57
- MM2003.61
- RSI 1458.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+6.47%
200-day average slope, 3 months
+18.82%
50-day average slope, 1 month
+3.01%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
4.02 % per day
Volatility change
+1.74%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 0.06 (5) | 0.14 (1) | 2 988 (5) | 81 (4) | 34 (5) |
| 2027 | 0.12 (5) | 0.18 (1) | 3 664 (5) | 126 (4) | 68 (5) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 5, 2026.
Same sub-industry: 10 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PGNY | 7.2 | 7.5 | 2.7Md USD | 33.5x | 6.8 % | 8.9 % | 17.8 % | -3.1x | 6.7 % | 53.4 % | ||
| 2 | HQY | 7.0 | 6.8 | 8.5Md USD | 37.2x | 17.4 % | 7.6 % | 7.7 % | 1.4x | 5.7 % | 3.4 % | ||
| 3 | ELV | 6.8 | 6.7 | 92.8Md USD | 18.3x | 2.5 % | 1.4 % | 6.8 % | 3.0x | 7.0 % | 40.0 % | ||
| 4 | UNH | 6.8 | 6.7 | 361Md USD | 23.0x | 3.5 % | -0.4 % | 9.5 % | 1.8x | 6.3 % | 24.6 % | ||
| 5 | SAUD3 | 6.4 | 5.9 | 8.4Md USD | 16.8x | 10.6 % | 1213.1 % | 10.4 % | -0.3x | 1.5 % | 36.5 % | ||
| 6 | CNC | 5.8 | 5.8 | 34.9Md USD | 24.2x | 0.7 % | 1.9 % | 3.8 % | -1.4x | 11.3 % | 102.9 % | ||
| 7 | HUM | 4.9 | 3.5 | 53.6Md USD | 43.4x | 0.8 % | 26.1 % | 4.1 % | -2.2x | 5.9 % | 86.0 % | ||
| 8 | MOH | 4.7 | 2.8 | 10.9Md USD | Not meaningful (loss) | -0.1 % | -3.4 % | -0.6 % | -22.1x | 2.2 % | 47.1 % | ||
| 9 | CLOV | 4.5 | 1.9 | 2.6Md USD | 261.1x | 0.5 % | 52.9 % | — | — | — | 92.8 % |
